Novo Nordisk Temporarily Reduces Supply of Popular Obesity Drug Wegovy
TL;DR Summary
Novo Nordisk is cutting supply on certain dose strengths of its weight loss drug Wegovy due to strong demand, which will not meet anticipated patient demand. The company projected that many patients will have difficulty filling Wegovy prescriptions at these dose strengths through September 2023. However, it doesn't anticipate supply interruptions for its 1.7 mg and 2.4 mg dose strengths. Obesity care sales grew by 131% in Danish Kroner to DKK 7.8 billion, or $1.15 billion, which was mainly driven by the uptake of Wegovy in the US.
- Novo Nordisk cuts supply of certain Wegovy doses as it faces strong demand Fox Business
- Why You Might Not Be Able to Start Taking Wegovy The Wall Street Journal
- Novo Nordisk cuts some U.S. supply of Wegovy obesity drug as demand soars CNBC
- Amid high demand, Novo temporarily throttles US supply of low-dose Wegovy FiercePharma
- Novo Nordisk Stock, A Top 1% Stock, Skids On Light Obesity Sales | Investor's Business Daily Investor's Business Daily
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
83%
516 → 88 words
Want the full story? Read the original article
Read on Fox Business